AA
PCRX icon

Ancora Advisors’s Pacira BioSciences PCRX Stock Holding History

Ancora Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,400
Closed -$109K – 2022
2025
Q1 		$109K Buy
4,400
+3,000
+214% +$71.8K ﹤0.01% 839
2024
Q4 		$26.4K Buy
+1,400
New +$24.6K ﹤0.01% 1158

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Ancora Advisors's PCRX Position: Q2 2025 in Review

Ancora Advisors sold out of Pacira BioSciences (PCRX) in Q2 2025, closing a stake of 4,400 shares — an estimated $109K sold.

Ancora Advisors first reported a position in PCRX in Q4 2024 and held it in 2 quarters. The position peaked at $109K in Q1 2025. 233 funds tracked by Wall St. Rank hold PCRX as of Q2 2025.

  • Ancora Advisors reported no remaining Pacira BioSciences position as of Q2 2025 after selling out during the quarter.
  • Ancora Advisors sold 4,400 Pacira BioSciences shares in Q2 2025, an estimated $109K.
  • Ancora Advisors first reported a position in Pacira BioSciences in Q4 2024 and held it in 2 quarters.
  • Ancora Advisors's Pacira BioSciences position peaked at $109K in Q1 2025.
  • 233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2025.

Based on Ancora Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.